目次
第1章 グローバルゲノム編集市場 エグゼクティブサマリー
1.1. グローバルゲノム編集市場規模および予測（2022年～2032年）
1.2. 地域別概要
1.3. 分野別概要
1.3.1. サービス別
1.3.2. 技術別
1.3.3. 用途別
1.4. 主要トレンド
1.5. 不況の影響
1.6. アナリストの推奨事項と結論
第2章 グローバルゲノム編集市場の定義と調査の前提条件
2.1. 調査目的
2.2. 市場定義
2.3. 調査の前提条件
2.3.1. 対象範囲と除外範囲
2.3.2. 制限事項
2.3.3. 供給サイド分析
2.3.3.1. 可用性
2.3.3.2. インフラ
2.3.3.3. 規制環境
2.3.3.4. 市場競争
2.3.3.5. 経済的実現性
2.3.4. 需要側分析
2.3.4.1. 規制枠組み
2.3.4.2. 技術的進歩
2.3.4.3. 環境への配慮
2.3.4.4. 消費者意識と受容
2.4. 予測手法
2.5. 調査対象年
2.6. 通貨換算レート
第3章 世界のゲノム編集市場のダイナミクス
3.1. 市場推進要因
3.1.1. ゲノム編集技術の進歩
3.1.2. 創薬における用途の拡大
3.1.3. 精密医療における採用拡大
3.2. 市場の課題
3.2.1. 拡張性と製造の複雑性
3.2.2. ゲノム編集ツールの高コスト
3.3. 市場の機会
3.3.1. 治療における新たな用途
3.3.2. ゲノミクスへの研究開発投資の増加
3.3.3. 新興市場での採用拡大
第4章 世界のゲノム編集市場の業界分析
4.1. ポーターのファイブフォースモデル
4.1.1. 供給業者の交渉力
4.1.2. 購入業者の交渉力
4.1.3. 新規参入の脅威
4.1.4. 代替品の脅威
4.1.5. 競争上の競合
4.2. PESTEL分析
4.2.1. 政治
4.2.2. 経済
4.2.3. 社会
4.2.4. 技術
4.2.5. 環境
4.2.6. 法律
4.3. ゲノム編集における破壊的トレンド
4.4. 主な投資機会
4.5. 業界専門家による見解
第5章 ゲノム編集の世界市場規模および予測（2022年～2032年）
5.1. 製品
5.1.1. キット
5.1.2. 試薬
5.1.3. ライブラリー
5.1.4. ソフトウェア
5.2. サービス
5.2.1. gRNA合成
5.2.2. ベクター構築
第6章 ゲノム編集の世界市場規模および予測（2022年～2032年） 処置別
6.1. ノックアウト
6.2. ノックイン
第7章 ゲノム編集技術別 世界市場規模・予測（2022年～2032年）
7.1. CRISPR
7.2. ジンクフィンガーヌクレアーゼ（ZFN）
7.3. TALEN
第8章 用途別 世界市場規模・予測（2022年～2032年）
8.1. ゲノム編集
8.2. 創薬および医薬品開発
8.2.1. 血液疾患
8.2.2. 癌
8.2.3. 中枢神経系疾患
8.2.4. その他（眼科、感染症、ジストロフィー）
第9章 ゲノム編集の世界市場規模・予測（2022年～2032年）地域別
9.1. 北米
9.1.1. 米国
9.1.2. カナダ
9.2. ヨーロッパ
9.2.1. 英国
9.2.2. ドイツ
9.2.3. フランス
9.2.4. スペイン
9.2.5. イタリア
9.2.6. ヨーロッパのその他地域
9.3. アジア太平洋
9.3.1. 中国
9.3.2. インド
9.3.3. 日本
9.3.4. オーストラリア
9.3.5. 韓国
9.3.6. アジア太平洋地域その他
9.4. ラテンアメリカ
9.4.1. ブラジル
9.4.2. メキシコ
9.4.3. ラテンアメリカその他
9.5. 中東およびアフリカ
9.5.1. サウジアラビア
9.5.2. 南アフリカ
9.5.3. 中東およびアフリカのその他地域
第10章 競合情報
10.1. 主要企業のSWOT分析
10.1.1. Thermo Fisher Scientific Inc.
10.1.2. Merck KGaA
10.1.3. GenScript
10.2. 市場関係者が採用する主な戦略
10.3. 企業プロフィール
Thermo Fisher Scientific Inc.
Merck KGaA
GenScript
Agilent Technologies, Inc.
Revvity
Lonza
Tecan Trading AG
Sangamo Therapeutics
Precision BioSciences
Cellectis S.A.
Regeneron Pharmaceuticals Inc.
AMSBIO
Creative Biogene
Synthego
Takara Bio Inc.
第11章 研究プロセス
11.1. データマイニング
11.2. 分析
11.3. 市場推定
11.4. 検証
11.5. 出版
This remarkable growth is driven by transformative advancements in gene editing technologies and the widening spectrum of their applications across various sectors, including healthcare and biotechnology.
Gene editing represents a frontier in biotechnology, enabling precise alterations to genetic material. Key technological frameworks such as CRISPR-Cas9, TALENs, and Zinc Finger Nucleases (ZFNs) have revolutionized genetic engineering by making it more efficient, accessible, and versatile. With applications spanning drug discovery, therapeutic development, genome modification, and clinical diagnostics, the market has witnessed substantial adoption among pharmaceutical firms, research institutions, and biotechnology enterprises.
However, significant challenges persist. The scalability of gene editing solutions and the complexities of manufacturing consistent, high-quality tools remain pressing concerns, potentially impeding market growth. Despite these obstacles, the continuous influx of investments and focus on research and development underline the sector's promising future.
The gene editing market is bifurcated into two primary offerings: products and services. Products, including kits, reagents, libraries, and software, commanded the largest market share in 2023. Their essential role in various workflows, such as cell line engineering and drug development, underscores their significance. Services, encompassing gRNA synthesis and vector construction, also hold considerable promise, driven by increasing demand for precise genome editing solutions in drug discovery and therapeutic applications.
Geographically, North America emerged as the dominant regional market in 2023, bolstered by a surge in approvals for advanced therapies and a robust infrastructure supporting genomic research. Europe closely followed as the second-largest market, while the Asia Pacific region is poised for the fastest growth, attributed to heightened investments in R&D, adoption of genomics technologies, and advancements in genomic data analysis.
Key players driving innovation in the global gene editing market include Thermo Fisher Scientific Inc., Merck KGaA, GenScript, Agilent Technologies, Revvity, Lonza, Sangamo Therapeutics, and others. These industry leaders continue to explore novel applications, ensuring a competitive and rapidly evolving market landscape.
________________________________________
Major market players included in this report are:
• Thermo Fisher Scientific Inc.
• Merck KGaA
• GenScript
• Agilent Technologies, Inc.
• Revvity
• Lonza
• Tecan Trading AG
• Sangamo Therapeutics
• Precision BioSciences
• Cellectis S.A.
• Regeneron Pharmaceuticals Inc.
• AMSBIO
• Creative Biogene
• Synthego
• Takara Bio Inc.
________________________________________
The detailed segments and sub-segments of the market are explained below:
By Offerings
• Products
o Kits
o Reagents
o Libraries
o Software
• Services
o gRNA Synthesis
o Vector Construction
By Technique
• Knock-Out
• Knock-In
By Technology
• CRISPR
• Zinc Finger Nucleases (ZFN)
• TALEN
By Application
• Genome Editing
• Drug Discovery and Development
o Blood Disorders
o Cancer
o CNS Disorders
o Others (Ophthalmology, Infections, Dystrophies)
By Region
• North America
o U.S.
o Canada
• Europe
o UK
o Germany
o France
o Spain
o Italy
o Rest of Europe
• Asia Pacific
o China
o India
o Japan
o Australia
o South Korea
o Rest of Asia Pacific
• Latin America
o Brazil
o Mexico
o Rest of Latin America
• Middle East & Africa
o Saudi Arabia
o South Africa
o Rest of Middle East & Africa
Years Considered for the Study:
• Historic Year: 2022
• Base Year: 2023
• Forecast Period: 2024-2032
Key Takeaways:
• Market Estimates & Forecasts for 10 years (2022-2032).
• Annualized revenues and regional-level analysis for each market segment.
• Competitive landscape, including company profiles and SWOT analysis of top players.
• Insights into demand-side and supply-side dynamics, along with technological advancements.
Table of Content
Chapter 1. Global Gene Editing Market Executive Summary
1.1. Global Gene Editing Market Size & Forecast (2022-2032)
1.2. Regional Summary
1.3. Segmental Summary
1.3.1. By Offerings
1.3.2. By Technology
1.3.3. By Application
1.4. Key Trends
1.5. Recession Impact
1.6. Analyst Recommendation & Conclusion
Chapter 2. Global Gene Editing Market Definition and Research Assumptions
2.1. Research Objective
2.2. Market Definition
2.3. Research Assumptions
2.3.1. Inclusion & Exclusion
2.3.2. Limitations
2.3.3. Supply Side Analysis
2.3.3.1. Availability
2.3.3.2. Infrastructure
2.3.3.3. Regulatory Environment
2.3.3.4. Market Competition
2.3.3.5. Economic Viability
2.3.4. Demand Side Analysis
2.3.4.1. Regulatory Frameworks
2.3.4.2. Technological Advancements
2.3.4.3. Environmental Considerations
2.3.4.4. Consumer Awareness & Acceptance
2.4. Estimation Methodology
2.5. Years Considered for the Study
2.6. Currency Conversion Rates
Chapter 3. Global Gene Editing Market Dynamics
3.1. Market Drivers
3.1.1. Advancements in Gene Editing Technologies
3.1.2. Expanding Applications in Drug Discovery
3.1.3. Growing Adoption in Precision Medicine
3.2. Market Challenges
3.2.1. Scalability and Manufacturing Complexities
3.2.2. High Costs of Gene Editing Tools
3.3. Market Opportunities
3.3.1. Emerging Applications in Therapeutics
3.3.2. Rising R&D Investments in Genomics
3.3.3. Increasing Adoption in Emerging Markets
Chapter 4. Global Gene Editing Market Industry Analysis
4.1. Porter’s Five Force Model
4.1.1. Bargaining Power of Suppliers
4.1.2. Bargaining Power of Buyers
4.1.3. Threat of New Entrants
4.1.4. Threat of Substitutes
4.1.5. Competitive Rivalry
4.2. PESTEL Analysis
4.2.1. Political
4.2.2. Economical
4.2.3. Social
4.2.4. Technological
4.2.5. Environmental
4.2.6. Legal
4.3. Disruptive Trends in Gene Editing
4.4. Key Investment Opportunities
4.5. Industry Expert Perspectives
Chapter 5. Global Gene Editing Market Size & Forecast by Offerings (2022-2032)
5.1. Products
5.1.1. Kits
5.1.2. Reagents
5.1.3. Libraries
5.1.4. Software
5.2. Services
5.2.1. gRNA Synthesis
5.2.2. Vector Construction
Chapter 6. Global Gene Editing Market Size & Forecast by Technique (2022-2032)
6.1. Knock-Out
6.2. Knock-In
Chapter 7. Global Gene Editing Market Size & Forecast by Technology (2022-2032)
7.1. CRISPR
7.2. Zinc Finger Nucleases (ZFN)
7.3. TALEN
Chapter 8. Global Gene Editing Market Size & Forecast by Application (2022-2032)
8.1. Genome Editing
8.2. Drug Discovery and Development
8.2.1. Blood Disorders
8.2.2. Cancer
8.2.3. CNS Disorders
8.2.4. Others (Ophthalmology, Infections, Dystrophies)
Chapter 9. Global Gene Editing Market Size & Forecast by Region (2022-2032)
9.1. North America
9.1.1. U.S.
9.1.2. Canada
9.2. Europe
9.2.1. UK
9.2.2. Germany
9.2.3. France
9.2.4. Spain
9.2.5. Italy
9.2.6. Rest of Europe
9.3. Asia Pacific
9.3.1. China
9.3.2. India
9.3.3. Japan
9.3.4. Australia
9.3.5. South Korea
9.3.6. Rest of Asia Pacific
9.4. Latin America
9.4.1. Brazil
9.4.2. Mexico
9.4.3. Rest of Latin America
9.5. Middle East & Africa
9.5.1. Saudi Arabia
9.5.2. South Africa
9.5.3. Rest of Middle East & Africa
Chapter 10. Competitive Intelligence
10.1. Key Company SWOT Analysis
10.1.1. Thermo Fisher Scientific Inc.
10.1.2. Merck KGaA
10.1.3. GenScript
10.2. Top Strategies Adopted by Market Players
10.3. Company Profiles
10.3.1. Thermo Fisher Scientific Inc.
10.3.2. Merck KGaA
10.3.3. GenScript
10.3.4. Revvity
10.3.5. Lonza
10.3.6. Sangamo Therapeutics
10.3.7. Tecan Trading AG
10.3.8. Precision BioSciences
10.3.9. Cellectis S.A.
10.3.10. Regeneron Pharmaceuticals Inc.
10.3.11. AMSBIO
10.3.12. Creative Biogene
10.3.13. Synthego
10.3.14. Takara Bio Inc.
10.3.15. Bio-Techne
Chapter 11. Research Process
11.1. Data Mining
11.2. Analysis
11.3. Market Estimation
11.4. Validation
11.5. Publishing
❖ 掲載企業 ❖
Thermo Fisher Scientific Inc.、Merck KGaA、GenScript、Agilent Technologies, Inc.、Revvity、Lonza、Tecan Trading AG、Sangamo Therapeutics、Precision BioSciences、Cellectis S.A.、Regeneron Pharmaceuticals Inc.、AMSBIO、Creative Biogene、Synthego、Takara Bio Inc.など
❖ 免責事項 ❖
http://www.globalresearch.jp/disclaimer
